Pilot Study Exploring the Effect of Its Oral T Therapy, KYZATREX®on Male Fertility

[madman]

Marius Pharmaceuticals Announces Pilot Study Exploring the Effect of Its Oral Testosterone Therapy, KYZATREX® (CIII testosterone undecanoate capsules), on Male Fertility

Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, today announced it has initiated a pilot study to better understand the effect of oral testosterone replacement therapy, KYZATREX® (testosterone undecanoate), on spermatogenesis…

www.biospace.com

 

[madman]

RALEIGH, N.C., Jan. 9, 2024 /PRNewswire/ -- Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, today announced it has initiated a pilot study to better understand the effect of oral testosterone replacement therapy, KYZATREX® (testosterone undecanoate), on spermatogenesis in adult males. KYZATREX is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

While it is generally accepted that TRT in males decreases spermatogenesis, which occurs through suppression of the hypothalamic-pituitary-gonadal axis, most data are derived from traditional routes of administration of TRT (e.g., injections, patches, gels, implantable pellets, etc.). This study will be the first of its kind to specifically examine the effects of an oral TRT, like KYZATREX, on spermatogenesis. Importantly, the American Urological Association currently recommends that physicians prescribing TRT inform their patients of the risks of the therapy on fertility.

"We are eager to begin this new pilot study, as finding an option of TRT that does not reduce fertility in men would be a significant milestone in the field of andrology and society as a whole," said Andrew Sun, M.D., Director at the Center for Men's Health at Urology Partners of North Texas and Chief Medical Advisor for Marius Pharmaceuticals. "Too many men are suffering in silence from the effects of testosterone deficiency, and the results from this study could help us better understand the effects of oral TRT on spermatogenesis, which might potentially benefit a subset of men; those who are looking to start a family while still treating their low T."

Led by principal investigator Dr. Mohit Khera, Director of the Laboratory for Andrology Research Baylor College of Medicine, the study will enroll 20 male patients, ages 18-49 years old, who meet the American Urological Association's criteria for hypogonadism and who have not previously used TRT. "Historically, testosterone products have been known to impair sperm production. Thus, many young hypogonadal men planning to achieve a pregnancy are unable to use testosterone due to an increased risk of suppressing their sperm production," said Dr. Khera. "Identifying testosterone therapy that could potentially not suppress sperm production would be a significant advancement in the way we treat these hypogonadal men."

Participating patients will receive 200-400mg of KYZATREX BID for three months. Two semen analyses will be performed at baseline, one month, and three months, to assess any changes in each patient's sperm count. Blood draws will also be taken at each of these time points to measure testosterone, hormones, lipids, and hematocrit. There will also be an additional blood draw two weeks after starting the therapy to support drug titration to reach therapeutic levels. Additionally, patients will receive the IIEF, PHQ-9, and SF36 questionnaires at baseline and at the conclusion of the study to assess symptoms of low testosterone.

This pilot study is part of Marius Pharmaceuticals' comprehensive effort to develop innovative therapies for testosterone deficiency. To learn more about KYZATREX, visit https://www.kyzatrex.com. To learn more about Marius Pharmaceuticals, visit https://www.mariuspharma.com.

 

[madman]

Oral TRT Products: Jatenzo, Tlando, Kyzatrex, & DiTest

Testosterone Replacement Therapy: A Narrative Review with a Focus on New Oral Formulations (2022) Salman Z Bhat and Adrian S Dobs Male hypogonadism affects 10–30% of the male population and is often under-recognized and under-treated. Different replacement formulations exist, each with...

www.excelmale.com

Oral Testosterone: The New Frontier of TRT

https://www.prostatehealthpodcast.com/84-oral-testosterone-the-new-frontier-of-testosterone-replacement-therapy-with-wayne-kuang-md/#testosterone We are excited to partner with Marius Pharmaceuticals for today’s podcast and have Dr. Wayne Kuang joining us as our featured guest! Until...

www.excelmale.com

Testosterone: Navigating Options & Implementation in Clinical Practice

Great interview! Very thorough. This video discusses the importance of men’s health and the role of urologists in addressing conditions like testosterone deficiency. Key Takeaways: *Dr. Andrew Sun provides an overview of different testosterone treatment options, including both internal...

www.excelmale.com